Reports and Data.jpeg-01
Ankylosing Spondylitis Drugs Market To Reach USD 8.82 Billion By 2027 | Reports And Data
February 11, 2020 16:00 ET | Reports and Data
New York, Feb. 11, 2020 (GLOBE NEWSWIRE) -- The global ankylosing spondylitis drugs market is forecast to reach USD 8.82 Billion by 2027, according to a new report by Reports and Data. Ankylosing...
1547522887207_5c33aa745c253600048c1b5f_logo.jpg
Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International
February 06, 2020 08:11 ET | Amarantus Bioscience Holdings, Inc.
New York, NY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Appoints Timothy Compton as Chief Commercial Officer
January 08, 2020 08:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2020 and Recent Developments
December 09, 2019 16:05 ET | Avid Bioservices, Inc
-- Achieved Strong Second Quarter Revenue of $18.3 Million and Gross Margin of 18% -- -- Fiscal 2020 Projected Revenue of $64 to $67 Million Reaffirmed -- -- Launched Expanded Process Development...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
December 04, 2019 16:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2020 After Market Close on December 9, 2019
December 02, 2019 08:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Cytovance_HepaLink_Digtial_032017.jpg
Cytovance® Biologics Introduces an Integrated Single-use Platform for Plasmid DNA (pDNA) Manufacture
October 21, 2019 12:00 ET | Cytovance Biologics
OKLAHOMA CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Cytovance Biologics is a leading biopharmaceutical CDMO with a 15-year track record of supplying drug substance to clients, offering fast and...
Cytovance_HepaLink_Digtial_032017.jpg
Cytovance Biologics to Participate in RAFT Scientific Discussion on Commercialization of Fermentation Processes
October 18, 2019 17:24 ET | Cytovance Biologics
OKLAHOMA CITY, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company will participate...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Names Richard Richieri as Chief Operations Officer
October 09, 2019 12:30 ET | Avid Bioservices, Inc
TUSTIN, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Announces Completion of Expansion of Process Development Capabilities and Laboratory Infrastructure
October 08, 2019 08:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...